Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
non-small cell lung cancer
Biotech
Prelude calls it curtains on lead SMARCA2 cancer asset
The biotech is directing energy toward another SMARCA2 degrader, its sole remaining clinical-stage asset.
Darren Incorvaia
Aug 14, 2025 10:44am
Instil's licensed PD-L1xVEGF bispecific shows promise in China
Jul 31, 2025 2:10pm
Royalty signs off $2B to bankroll Revolution's RAS cancer drug
Jun 24, 2025 9:00am
Nuvalent trots out strong pivotal data in FDA lung cancer push
Jun 24, 2025 6:30am
ASCO: Cullinan drug sees 35% ORR in pretreated NSCLC
May 22, 2025 5:00pm
Roche nets FDA breakthrough label for AI lung cancer CDx test
Apr 29, 2025 2:07pm
